ALAudrey R. Lloyd

Audrey R. Lloyd

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Audrey R. Lloyd has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Breastfeeding Period: A Critical Opportunity to Expand Access to Hepatitis C Cure

    by Audrey R Lloyd

    Women living with hepatitis C virus (HCV) must often choose between breastfeeding or accessing HCV cure. The analysis reported by McCrary et al on the pharmacokinetics of glecaprevir-pibrentasvir in breast milk lays important groundwork to support future studies informing safety.

  • Open Access

    Female Sex is Protective Against MASLD With Clinically Significant Fibrosis in a Large Cross-sectional Cohort of Persons With HIV

    by Kara Wegermann, Ayako Suzuki, Elisa Sarmiento, LaKeisha Boyd, Yang Li, Laura A Wilson, Audrey Lloyd, Paula Debroy, Jennifer C Price, Tinsay Woreta, et al.

    Background: Men are at higher risk for metabolic dysfunction-associated steatotic liver disease (MASLD) with clinically significant fibrosis (CSF) than premenopausal women, but data are lacking in persons with HIV (PWH). The aim of this study was to discover prevalence and severity of MASLD in PWH by sex assigned at birth and menopausal status. Methods: We examined participants from the prospective, cross-sectional HIV NASH CRN who had suppressed HIV-1 RNA, self-reported sex assigned at birth and menopause status, and underwent transient elastography (TE). The primary outcome was MASLD (controlled attenuation parameter [CAP] ≥ 263 dB/m, ≥1 cardiometabolic risk factor, Alcohol Use Disorders Identification Test score <8) with CSF (MASLD-CSF, TE Liver Stiffness Measurement ≥ 8 kPa). Results: Nine hundred and sixty-four PWH were included: 709 men (73.5%) and 255 women (26.5%) with similar median ages (55.1 and 56.6 years, P-value = .08). The most common race was Black (52%). Women had lower prevalence of MASLD-CSF than men (5.5% vs 10.6%, P = .02). In a multivariable logistic regression model for MASLD-CSF, diabetes (OR 3.26 [95% confidence interval 2.01–5.30], P < .0001), hyperlipidemia (1.97 [1.14–3.39], P = .02), and waist circumference (WC) above sex-specific cutoff (women: 80 cm, men: 94 cm) (4.59 [2.12–9.93], P < .0001) were associated with higher odds of MASLD-CSF, while female sex was associated with lower odds (0.43 [0.23–0.81], P = .01). Variables and effect sizes associated with MASLD-CSF differed among sex/menopause subgroups. Conclusions: Female sex was protective against MASLD-CSF in PWH. Men with diabetes, hyperlipidemia, and high WC would be candidates for MASLD screening. Further studies of PWH with women, especially more young women, are needed.


  • Open Access

    Plasma Microbial Cell-free DNA Sequencing for the Detection of Kingella kingae Pediatric Spinal Infections

    by Asim A. Ahmed, Sarah Y. Park, Matthew J. Smollin, Martin S. Lindner, Adriana Sarmiento Clemente, Ana Del Valle Penella, P. Marcelo Laufer, Carolina Sanchez-Vegas, Manuel R. Cotilla, Marian E. Melish, et al.

    Background: Diagnosis of Kingella kingae skeletal system infections is made challenging by the microbe’s fastidious nature. Detection and quantification of circulating microbial cell-free DNA (mcfDNA) in plasma by the Karius Test, a commercial metagenomic sequencing test, may offer promise in diagnosing pediatric spinal infections caused by difficult-to-culture organisms such as K. kingae. Methods: Plasma mcfDNA sequencing detections of K. kingae from April 2018 to December 2020 were reviewed to identify pediatric (age K. kingae spinal infections were identified across 7 institutions. The median age was 16.5 months (range 11–23 months). All case-patients had vertebral osteomyelitis with 9 having spondylodiscitis. Compared with usual care tests, mcfDNA sequencing was significantly more sensitive (McNemar’s test 6.25, 2-tailed P = 0.0133). It was the only method of microbiological diagnosis in 9 patients, providing results in a median of 2.5 days (range 2–5 days) from sample collection. K. kingae mcfDNA was detected despite antibiotic pretreatment in 5/5 case-patients. Pathogen-tailoring of antimicrobial coverage was undertaken in 9 children. Conclusion: Plasma mcfDNA sequencing offers a rapid, noninvasive method of detecting K. kingae causing pediatric spinal infections. This culture-independent approach may facilitate diagnosis, despite antibiotic pretreatment and subsequently targeted therapy and potentially obviate the need for biopsy.


  • Open Access

    Hepatitis C Virus Elimination Programs in Louisiana and Washington: Importance of Screening and Surveillance Systems

    by Andrew H. Talal, Arpan Dharia, Shashi N. Kapadia, Gia L. Tyson, Susan Mba Birch, Judy Zerzan-Thul, Donna Sullivan, Elizabeth Msn Britton, Elaine Wethington, Christopher J. Md Gonzalez, et al.

    The US government has established a national goal of hepatitis C virus (HCV) elimination by 2030. To date, most HCV elimination planning and activity have been at the state level. Fifteen states presently have publicly available HCV elimination plans. In 2019, Louisiana and Washington were the first states to initiate 5-year funded HCV elimination programs. These states differ on motivation for pursuing HCV elimination and ranking on several indicators. Simultaneously, however, they have emphasized several similar elimination components including HCV screening promotion through public awareness, screening expansion, surveillance enhancement (including electronic reporting and task force development), and harm reduction. The 13 other states with published elimination plans have proposed the majority of the elements identified by Louisiana and Washington, but several have notable gaps. Louisiana's and Washington's comprehensive plans, funding approaches, and programs provide a useful framework that can move states and the nation toward HCV elimination.


  • Opioid use disorder: a neglected human immunodeficiency virus risk in American adolescents

    by Audrey R. Lloyd, Rebekah Savage, Ellen F. Eaton

    In 2017 alone, 783 000 children aged 12–17 years misused opioids with 14 000 using heroin. Opioid misuse and opioid use disorder (OUD) in adolescents and young adults are significant barriers to ending the HIV epidemic. To address these synergistic scourges requires dedicated practitioners and improved access to life-saving evidence-based treatment. Adolescents and young adults make up over one in five new HIV diagnoses even though they are less likely to be tested or know they are infected. Adolescents and young adults living with HIV are less likely to be retained in care or achieve virological suppression. OUD further leads to increased rates of risky behaviours (like sex without condoms), deceased retention in HIV care and decreased rates of viral suppression in this vulnerable population. Medications for opioid use disorder (MOUD) are recommended for adolescents and young adults with severe OUD and help retain youth in HIV treatment and decrease risk of death. However, due to stigma and lack of experience prescribing MOUD in adolescents, MOUD is often perceived as a last line option. MOUD remains difficult to access for adolescents with a shortage of providers and decreased options for treatment as compared to adults. Addiction treatment is infection prevention, and integrated addiction and HIV services are recommended to improve health outcomes. A multipronged approach including patient education, provider training and policy changes to improve access to treatment and harm reduction are urgently needed confront the drug use epidemic in youth.